← ANALYST RATINGS · TIPRANKS
Cormedix (CRMD): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $14.50, the highest $15.00, the lowest $14.00. The average is +99.7% from the last price of $7.26.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% | RBC Capital | $14.00 | Buy | +92.8% | Reiterated | 08.10.26on TipRanks 21:45 | +0.2%next day +1.1% · 5 days +0.3% | ↗ |
| Unknown Analyst | Oppenheimer | $15.00 | Buy | +106.6% | Initiated | 23.09.26on TipRanks Sep 30 21:09 | −0.4%next day +1.1% · 5 days +0.8% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $9.50 | Buy | +30.9% | Reiterated | 27.08.26on TipRanks Aug 26 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $10.00 | Buy | +37.7% | Reiterated | 27.08.26on TipRanks Aug 26 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $9.50 | Buy | +30.9% | Reiterated | 27.08.26on TipRanks Aug 26 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $9.50 | Buy | +30.9% | Upgrade | 27.08.26on TipRanks Aug 26 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $10.00 | Buy | +37.7% | Reiterated | 27.08.26on TipRanks Aug 26 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $10.00 | Buy | +37.7% | Reiterated | 27.08.26on TipRanks Aug 26 23:05 | — | |
| Brandon Folkes★★★★★★★★★★#10500 · hits 39% · avg −1.1% | H.C. Wainwright | $13.00 | Buy | +79.1% | Reiterated | 14.08.26on TipRanks 06:25 | −7.2%next day +2.2% · 5 days +10.1% | ↗ |
| Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% | Needham | $15.00 | Buy | +106.6% | Reiterated | 13.08.26on TipRanks 13:25 | +14.0%next day −7.2% · 5 days +3.1% | ↗ |
| Roanna Ruiz★★★★★★★★★★#9351 · hits 46% · avg −0.3% | Leerink Partners | $14.00 → $15.00+7.1% | Buy | +106.6% | Reiterated | 15.05.26on TipRanks 11:20 | −3.6%next day +4.8% · 5 days +4.8% | ↗ |
| Jason Kolbert★★★★★★★★★★#12335 · hits 32% · avg −9.0% | D. Boral Capital | $14.00 | Buy | +92.8% | Upgrade | 20.10.25on TipRanks 09:45 | +18.4%next day −4.2% · 5 days −11.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Cormedix
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $14.25 at a price of $7.70 (+85.1%); now: $14.25 at $7.26 (+96.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 6 | 2 | 2 | 2 | 3 |
| Buy | 3 | 2 | 2 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.10 (from $-0.17 to $-0.05). Last quarter: $0.29.
Sales
Next quarter’s sales estimate — $53M (from $51M to $58M). Last quarter: $102M.
Best top-analyst consensus in the sector · Healthcare
About Cormedix
- CEO: Joseph Todisco
- Employees: 191
- 389 Interpace Pkwy, Parsippany, NJ, 07054, US
- www.cormedix.com
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
Data from the stock’s TipRanks forecast page, read 46 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗